Summit starts phase 3 trial of ivonescimab in lung cancer
Summit Therapeutics (NASDAQ: SMMT) launched a Phase III trial (HARMONi-10) for ivonescimab in lung cancer, comparing it to durvalumab. The trial aims to evaluate progression-free survival as the primary endpoint, with global site activations expected in Q4 2026. Ivonescimab, a PD-1 x VEGF bispecific antibody, is not approved in the U.S. or Europe but has marketing authorization in China. Over 5,000 patients have been treated in clinical studies globally, and over 100,000 in China.
How this was made
The 30-second read
Why it matters
The Phase III start is the first public indication of a new pivotal study, providing a fresh catalyst for the stock. Investors will watch for enrollment speed and early safety signals.
Market read
The announcement adds a new near‑term catalyst for Summit Therapeutics, with potential spill‑over to other oncology biotech stocks.
What to watch
The drug already has Chinese approval; success in the U.S. could unlock a large new market beyond current revenues.
Background
Summit Therapeutics (NASDAQ:SMMT) is a clinical‑stage biotech focused on bispecific antibodies. Ivonescimab is already approved in China and is being evaluated against the current standard durvalumab in the U.S. and Europe.
Ticker impact
Summit Therapeutics announced the initiation of the global Phase III HARMONi-10 trial for ivonescimab in Stage III non‑small cell lung cancer.
potential modest upside as investors price in trial progress, with downside risk if early data are negative
Phase III initiation is a material development for a biotech; market typically reacts to trial milestones, but the impact will unfold over months.
Market effects
Adds to the pipeline momentum in the oncology biotech sector, potentially lifting peers developing PD‑1/VEGF bispecifics.
Limited to U.S. and European biotech markets; no immediate macro effect.
Modest, as the trial is global but impact is confined to biotech investors.
Counterpoint
If the market has already priced in optimism, a neutral or negative trial read could trigger a sell‑off.
Key entities
- companySummit Therapeutics Inc.
Biotech developer of ivonescimab, listed on NASDAQ under SMMT.
- companyAkeso Inc.
Chinese partner that commercializes ivonescimab in China (HKEX:9926.HK).


